Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance PIOMBINO DESE, Italy / Aug 05, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter... Read More